UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

FORM 8-K

CURRENT REPORT

Pursuant To Section

13 or 15(d) of the Securities Exchange Act of 1934

Date of report:

November 30, 2006

Date of earliest event reported: November 30, 2006

PFIZER

INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction of incorporation)

1-3619

(Commission File Number)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive

offices) (zip code)

(212) 573-2323

(Registrant's telephone number)

Check the appropriate box below if the Form 8-K filing is

intended to simultaneously satisfy the obligation of the registrant under any

of the following provisions:

[ ] Written communication pursuant to Rule

425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

[ ] Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

Item 8.01. Other

Events

Exhibit 100 to this Current

Report on Form 8-K contains documents formatted in XBRL (eXtensible Business

Reporting Language) with information from Pfizer Inc.'s Quarterly Report on

Form 10-Q for the quarter ended April 2,

2006, filed with the Securities and

Exchange Commission (SEC) on May 8,

2006. The information formatted in XBRL

includes the (i) Condensed Consolidated Statements of Income for the three months ended

April 2, 2006 and April 3, 2005, (ii) Condensed Consolidated

Balance Sheets at April 2, 2006 and December 31, 2005, and (iii) Condensed

Consolidated Statements of Cash Flows for the three months ended April 2, 2006 and

April 3, 2005.

Users of this data are

advised pursuant to Rule 401 of Regulation S-T that the financial information

contained in the XBRL-Related Documents is unaudited and these are not the official

financial statements of Pfizer Inc. as filed with the SEC. The purpose of

furnishing these XBRL formatted documents is solely for the purpose of participation

in the SEC's voluntary XBRL pilot program to test the related format and

technology and, as a result, investors should continue to rely on the official

filed version of the furnished documents and not rely on the information in

this Current Report on Form 8-K, including Exhibit 100, in making investment

decisions.

In accordance with Rule

402 of Regulation S-T, the information in this Current Report on Form 8-K,

including Exhibit 100, shall not be deemed to be "filed" for purposes

of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange

Act"), or otherwise subject to the liability of that section, and shall

not be incorporated by reference into any registration statement or other

document filed under the Securities Act of 1933, as amended, or the Exchange

Act, except as shall be expressly set forth by specific reference in such

filing.

Item 9.01. Financial

Statements and Exhibits.

(d)

Exhibits

The following exhibits are

furnished herewith:

Exhibit Number

Exhibit Description

100

The following financial

statements from Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter

ended April 2, 2006, filed on May 8, 2006, formatted in XBRL (eXtensible

Business Reporting Language): (i) the Condensed Consolidated Statements of Income

for the three months ended April 2, 2006 and April 3, 2005, (ii) the

Condensed Consolidated Balance Sheets at April 2, 2006 and December 31, 2005,

and (iii) the Condensed Consolidated Statements of Cash Flows for the three months ended

April 2, 2006 and April 3, 2005.

SIGNATURE

Under the requirements of the

Securities Exchange Act of 1934, the registrant has caused this report to be

signed on its behalf by the authorized undersigned.

PFIZER INC.

By:

/s/ Margaret M. Foran

Margaret M. Foran

Dated: November 30, 2006

Title: Senior Vice

President-Corporate Governance

Associate General Counsel and Corporate Secretary

EXHIBIT INDEX

Exhibit No.

Description

EX-100.INS

XBRL Instance Document

EX-100.SCH

XBRL Taxonomy Extension

Schema Document

EX-100.SCH.1

XBRL Schema Supplement Document

EX-100.CAL

XBRL Taxonomy Extension

Calculation Linkbase Document

EX-100.LAB

XBRL Taxonomy Extension

Label Linkbase Document

EX-100.PRE

XBRL Taxonomy Extension

Presentation Linkbase Document